Albuquerque Center for Rheumatology

Albuquerque, New Mexico 87102-1710

0 studies enrolling now · 26 studies all time

What they study most

Active Cutaneous Lupus Erythematosus, Active Psoriatic Arthritis, Arthritis, Arthritis, Psoriatic, Arthritis, Rheumatoid, Autoimmune Diseases, Chronic Cutaneous Lupus Erythematosus, Connective Tissue Diseases, Gout, Gout Flare, Hyperuricemia, Immune System Diseases

Studies at this site

• A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus — Running, not enrolling
• Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD — Running, not enrolling
• Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent — Running, not enrolling
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Completed
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight — Completed
• Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis — Running, not enrolling
• A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's — Running, not enrolling
• A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State — Running, not enrolling
• A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis — Stopped early
• Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients — Completed
• A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus — Stopped early
• Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) — Completed
• A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus — Stopped early
• Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) — Completed
• Effects of Abatacept in Patients With Early Rheumatoid Arthritis — Completed
• Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis — Completed
• A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy — Stopped early
• Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis — Completed
• Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis — Completed
• Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate — Completed
• Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe — Completed
• Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis — Stopped early
• Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis — Stopped early
• BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis — Completed
• A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis — Completed
• A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors — Completed